Navigation Links
PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
Date:6/4/2008

BOSTON, Mass., June 4 /PRNewswire-FirstCall/ -- Experts with in-depth product development and regulatory strategy experience from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, will attend the 2008 BIO International Convention to be held June 17-20, 2008 at the San Diego Convention Center in San Diego, California. PAREXEL has worked with the top 10 global biotechnology companies, and has helped hundreds of small and mid-size biopharmaceutical companies develop and implement product and regulatory strategies as well as maximize product value at every milestone and phase of development.

PAREXEL is a sponsor of the Business Forum, one of the largest partnering events in the world, which will be held during the BIO convention. The Business Forum offers opportunities for biotechnology and pharmaceutical companies, academic institutions, and investors to present, meet, and discuss business opportunities of mutual interest.

Biopharmaceutical companies attending the BIO convention can visit Booth 1337 to speak with PAREXEL experts about integrated solutions to help them reach critical clinical milestones and successfully develop products for regional and international markets. Attendees can learn about PAREXEL's expertise in product development, all phases of clinical research, enabling eClinical technologies, and medical communications. Additionally, companies can find out how to leverage PAREXEL's global platform, providing a wide array of geographies in which to conduct clinical development programs, and access local and global regulatory experience.

Hosted by the Biotechnology Industry Organization (BIO), the 2008 BIO International Convention will bring together more than 20,000 industry and business leaders, scientists, and investors from more than 60 countries. The convention will address the drivers behind new medicine, processes, and other areas of the global biotechnology industry.

For more information about PAREXEL visit http://www.PAREXEL.com or Booth 1337 at the BIO convention.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Public Relations

PAREXEL International

Email: Jennifer.Baird@PAREXEL.com

+781-434-4409

Rebecca Passo

SHIFT Communications

Email: rpasso@shiftcomm.com

+617-779-1817


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
2. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
3. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
4. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
5. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
6. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
8. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
9. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
10. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... ... 24, 2017 , ... It is well established that ligand ... broad application of this cellular target engagement concept to drug discovery has been ... stabilization assays are valuable methods for particular applications, but they can require target-specific ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):